(paliperidone palmitate)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA SUSTENNA® (paliperidone palmitate)
Medical Information
INVEGA SUSTENNA - Specific Populations - Geriatric Use
Last updated : 11/11/2024
SPECIFIC RESPONSE
INVEGA SUSTENNA is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment, who should be given reduced doses.1,2
Because elderly patients are more likely to have decreased renal function, adjust dose based on renal function.1,2
References
Show Hide
1.INVEGA SUSTENNA [(paliperidone palmitate) Extended-Release Injectable Suspension] [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-54c7ff1c-5e50-4845-a605-24e8c5104cd7.
2. Samtani MN, Gopal S, Kern Sliwa J, et al. Paliperidone palmitate dosing in special populations including the elderly and those with renal impairment or differing in body mass index: guidance based on pharmacokinetic modeling and simulation. Poster presented at: The American Conference on Pharmacometrics; October 4-7, 2009; Mashantucket, CT.
